{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:29:14Z","timestamp":1767007754869,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clgc.2013.11.019","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T16:16:53Z","timestamp":1384359413000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma"],"prefix":"10.1016","volume":"12","author":[{"given":"David T.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali-Reza","family":"Golshayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"E. Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzair","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2013.11.019_bib1","unstructured":"American Cancer Society. Cancer Facts & Figures\u00a02012. Available at: http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-031941.pdf. Accessed: August 1,\u00a02013."},{"key":"10.1016\/j.clgc.2013.11.019_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.10657","article-title":"Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era","volume":"95","author":"D'Amico","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2013.11.019_bib3","first-page":"876","article-title":"High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer","volume":"166","author":"Zelefsky","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.11.019_bib4","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1200\/JCO.2005.01.2906","article-title":"Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy","volume":"23","author":"Zhou","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","article-title":"Mechanisms underlying the development of androgen-independent prostate cancer","volume":"12","author":"Pienta","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.019_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.019_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.019_bib9","first-page":"229","article-title":"Bcl2 is the guardian of microtubule integrity","volume":"57","author":"Haldar","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.019_bib10","first-page":"4191","article-title":"Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in\u00a0vivo","volume":"5","author":"Mason","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"2 suppl 1","key":"10.1016\/j.clgc.2013.11.019_bib11","first-page":"12","article-title":"Combination of taxanes with radiation: preclinical studies","volume":"9","author":"Milas","year":"1999","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.2004.02.001","article-title":"Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate","volume":"22","author":"Kumar","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.urolonc.2007.04.003","article-title":"Phase I\/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10)","volume":"26","author":"Perrotti","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2010.08.012","article-title":"Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial","volume":"97","author":"Bolla","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2010.06.042","article-title":"Long-term results of a prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer","volume":"81","author":"Dibiase","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2011.10.015","article-title":"A\u00a0phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2013.11.019_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0090-4295(02)02519-0","article-title":"Neoadjuvant docetaxel and estramustine chemotherapy in high-risk\/locally advanced prostate cancer","volume":"61","author":"Hussain","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2013.11.019_bib18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.019_bib20","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.019_bib21","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.019_bib22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.299.8.898-c","article-title":"Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate","volume":"299","author":"Zietman","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2013.11.019_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2008.04.063","article-title":"Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer","volume":"73","author":"Al-Mamgani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib26","first-page":"1549","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.11.019_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1607-551X(09)70118-4","article-title":"Relationships between American Urological Association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia","volume":"20","author":"Liu","year":"2004","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.clgc.2013.11.019_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0360-3016(02)04279-7","article-title":"Dysuria after permanent prostate brachytherapy","volume":"55","author":"Merrick","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0360-3016(95)02050-0","article-title":"Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer","volume":"35","author":"Stock","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2013.11.019_bib30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313002905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313002905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:27Z","timestamp":1761564207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767313002905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1558767313002905"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2013.11.019","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2013.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}